Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: A

Drug products: ADARTREL, Requip, Requip Depot, Requip®, Ropinirol 2care4, Ropinirol Ebb, Ropinirol Krka, Ropinirol Mylan, Ropinirol Sandoz, Ropinirol Stada, Ropinirole Orifarm, Ropinirole Teva

ATC code: N04BC04

Substances: ropinirole, ropinirole hydrochloride


The main indication of ropinirol is treatment for Parkinson Disease but the drug is also used in Restless Legs Syndrome (RLS). Clinical studies have shown ropinirol up to 4 mg/day have no exposure related effects on the mean of QT interval in healthy men and women.
Clinical studies have shown that oral doses as low as 0.2 mg suppressed serum prolactin concentration in healthy men.
In our opinion, the described differences do not motivate differentiated dosing or treatment in men and women.

Additional information

Pharmacokinetics and dosing

Oral clearance of ropinirol have shown to be similar in men and women [1]. Ropinirol is indicated for treatment of Parkinson’s disease and for treatment of Restless Legs Syndrome. Therapy with ropinirol is initiated at a low dose and gradually titrated upward according to clinical tolerability to obtain the optimum therapeutic effect. It is not necessary to adjust the initial dose based on sex [1].


No studies with a clinically relevant sex analysis regarding the effects of ropinirol have been found .

Adverse effects

Ropinirol have shown to have no dose- or exposure-related effect on mean QT intervals in healthy men and women titrated to doses up to 4 mg/day [1].

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Other information

At oral doses as low as 0.2 mg, ropinirol suppressed serum prolactin concentrations in healthy men [1].

Updated: 2019-02-26

Date of litterature search: 2013-04-02


  1. Requip (ropinirole). DailyMed [www]. US National Library of Medicine. [updated 2012-07-01, cited 2013-04-02]. länk
  2. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-29] länk

Authors: Linnéa Karlsson Lind, Desirée Loikas

Reviewed by: Expertrådet för neurologiska sjukdomar

Approved by: Mia von Euler